Default company panoramic image

Canterbury Laboratories, LLC

Canterbury is engaged in science-based premium cosmeceuticals that revitalize hormonally aged skin and hair in women over 45 years of age.

  • Stage Product In Development
  • Industry Consumer Products
  • Location Holden, MA, USA
  • Currency USD
  • Founded October 2011
  • Employees 3

Company Summary

Canterbury’s proprietary ingredients bring a new, differentiated benefit to the anti-aging market. Our topical principal performance ingredients safely halt and reverse age-related hormonal changes in women’s skin and hair. Unlike other anti-aging topical cosmeceuticals, Canterbury’s topical principal performance ingredients act only at the point of application, are non-irritating and spare internal organs from unnecessary systemic exposure.


  • Default avatar
    Yael Schwartz
    President and CEO, Founder, Director

    More than 25 years experience as a pharmaceutical scientist/manager/educator with advanced training in pharmacology, toxicology, human physiology and immunology. Proven track record of advancing small molecule therapeutics from discovery through NDA submission in multiple therapeutic areas. Identified and in-licensed drug candidates in dermatology and women's health. Identified and worked closely with thought leaders in respiratory, CNS, dermatol

  • Default avatar
    Julie Burrows

    A Business Team Leader and Marketing Executive experienced in delivering outstanding results on consumer businesses. Led many turnaround situations, improving growth prospects and profitability for many product lines Experience in internet products and media gives Julie a wealth of current tools to improve any products’ consumer interactivity and ROI. Her skills in strategy development, branding, and new products, as well as her intelligence, cre

  • Default avatar
    Craig Abolin
    CSO, Co-Founder

    More than thirty (30) years’ experience in the healthcare/pharmaceutical industry. Craig has held senior positions with Sepracor, Novartis, Sandoz, Hygeia Therapeutics, Inc. and Astra Pharmaceuticals. He has been an integral part of teams that have placed more than fifteen (15) therapeutics into clinical practice.


  • Default avatar
    Peter B. Finn, Esq., Sr. Partner, Rubin and Rudman LLP
    Default avatar
    Bruce Gold,CPA, Abrams Little-Gill Loberfeld PC

Previous Investors

  • Default avatar
    Bioventures Investors
    Default avatar
    Private equity
    Default avatar